Russell Investments Group
IMUX icon

Russell Investments Group’s Immunic IMUX Stock Holding History

Russell Investments Group’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-84
Closed -$12K – 3153
2020
Q4 		$12K Sell
84
-846
-91% -$152K ﹤0.01% 2998
2020
Q3 		$172K Buy
+930
New +$152K ﹤0.01% 2822

Other funds holding IMUX

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Russell Investments Group's IMUX Position: Q1 2021 in Review

Russell Investments Group sold out of Immunic (IMUX) in Q1 2021, closing a stake of 84 shares — an estimated $12K sold.

Russell Investments Group first reported a position in IMUX in Q3 2020 and held it in 2 quarters. The position peaked at $172K in Q3 2020. 63 funds tracked by Wall St. Rank hold IMUX as of Q1 2021.

  • Russell Investments Group reported no remaining Immunic position as of Q1 2021 after selling out during the quarter.
  • Russell Investments Group sold 84 Immunic shares in Q1 2021, an estimated $12K.
  • Russell Investments Group first reported a position in Immunic in Q3 2020 and held it in 2 quarters.
  • Russell Investments Group's Immunic position peaked at $172K in Q3 2020.
  • 63 funds tracked by Wall St. Rank held Immunic as of Q1 2021.

Based on Russell Investments Group's 13F filing for Q1 2021, filed 10 May 2021.